Search Result

Results for "

cysteinyl leukotriene receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Leukotriene Receptor (15) G protein-coupled Bile Acid Receptor 1 (1) Isotope-Labeled Compounds (1) TNF Receptor (1)
By Research Areas:	Cardiovascular Disease (2) Inflammation/Immunology (14) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Leukotriene Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16780

Gemilukast ONO-6950	Leukotriene Receptor	Inflammation/Immunology
Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT₁ and CysLT₂) antagonist, with IC₅₀s of 1.7, 25 nM for human CysLT₁ and CysLT₂, respectively. Gemilukast is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13315

Montelukast sodium Maximum Cited Publications 8 Publications Verification MK0476	Leukotriene Receptor	Inflammation/Immunology
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-119442

Quininib	Leukotriene Receptor	Cardiovascular Disease
Quininib is a **cysteinyl leukotriene 1 and 2 receptor antagonist with IC₅₀s of 1.2 and 52 μM for CysLT₁R and CysLT₂R**, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents .

HY-105221

Masilukast ZD-3523	Leukotriene Receptor	Inflammation/Immunology
Masilukast is an orally administered **cysteinyl leukotriene D₄ (LTD₄) receptor** antagonist with potential to research asthma.

HY-112248

(Rac)-HAMI 3379	Leukotriene Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
(Rac)-HAMI 3379 is the racemate of HAMI 3379. HAMI 3379 is a potent and selective **Cysteinyl leukotriene (CysLT₂) receptor** antagonist .

HY-107609

BAY-u 9773	Leukotriene Receptor	Inflammation/Immunology
BAY-u 9773 is a non-selective antagonist of the CysLT receptors (cysteinyl leukotrienes receptors) with about the same IC₅₀ for CysLT ¹ and CysLT ². BAY-u9773 is used for the inhibition of LT responses .

HY-13315S1

Montelukast-d6 sodium MK0476-d₆	Leukotriene Receptor	Inflammation/Immunology
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-13315S

Montelukast-d6 MK0476-d₆ free acid	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology
Montelukast-d₆ is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-117854

SB 201146	Leukotriene Receptor	Inflammation/Immunology
SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma .

HY-165155

CysLT1 receptor antagonist-1	Leukotriene Receptor	Inflammation/Immunology
CysLT1 receptor antagonist-1 (Compound 4) is an antagonist for cysteinyl leukotriene receptor 1 (CysLT1R) with an IC₅₀ of 3.9 μM. CysLT1 receptor antagonist-1 exhibits weak agonist activity against *G-protein-coupled bile acid receptor* 1 (GPBAR1*) with an efficact of 23% at 10 μM. CysLT1 receptor* antagonist-1 can be used for asthma and allergic diseases researchs .

HY-13315A

Montelukast Maximum Cited Publications 8 Publications Verification MK0476 free base	Leukotriene Receptor	Inflammation/Immunology
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-13315B

Montelukast dicyclohexylamine MK0476 dicyclohexylamine	Leukotriene Receptor	Inflammation/Immunology
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .

HY-13315R

Montelukast sodium (Standard) MK0476 (Standard)	Leukotriene Receptor	Inflammation/Immunology
Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-13315AR

Montelukast (Standard)	Leukotriene Receptor	Inflammation/Immunology
Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-147086

CAY10789	Leukotriene Receptor G protein-coupled Bile Acid Receptor 1 TNF Receptor	Metabolic Disease Inflammation/Immunology
CAY10789 (compound 6) is a potent CysLT1R (cysteinyl leukotriene receptor 1) antagonist (IC₅₀=2.80 μM) and GPBAR1 (G-protein-coupled bile acid receptor 1) agonist (EC₅₀=3 μM). CAY10789 significantly reduces the adhesion of U937 cells to HAEC, reduces the expression of TNF-α. CAY10789 shows very promising metabolic stability and excellent pharmacokinetics. CAY10789 can be used for the research of colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .

Cat. No.	Product Name	Chemical Structure

HY-13315S1

Montelukast-d6 sodium
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

Montelukast-d6 sodium

Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-13315S

Montelukast-d6
Montelukast-d₆ is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.